Donor‐Derived Cell‐Free DNA Levels Predict Renal Allograft Biopsy Findings in a UK Single‐Centre Study. Results of the KORAD Study
International Journal of Immunogenetics · 2026-08 · 53 (4) · 332-343
DOI: 10.1111/iji.70055 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Immunogenetics, online erschienen am 28.05.2026. Verfasst von Patrick A Flynn und 2 weiteren Autor:innen. Beteiligte Einrichtung: Transplantation Laboratory, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK. Hauptthemen laut MEDLINE: Cell-Free Nucleic Acids, Kidney Transplantation, Graft Rejection. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National School of Healthcare Science Higher Specialist Scientist Training Programme.
Abstract (Originalsprache)
Prior studies have shown that donor‐derived cell‐free DNA (dd‐cfDNA) predicts renal biopsy‐defined transplant rejection with a high negative predictive value (NPV). However, these studies were not in UK‐based cohorts. The KORAD study aimed to assess relationships between dd‐cfDNA levels and biopsy‐defined rejection in a UK kidney transplant cohort, along with relationships with DSA and creatinine levels. dd‐cfDNA was determined using AlloSeq cfDNA (CareDx) and DSA was identified with LABScreen single‐antigen beads (Thermo Fisher Scientific). Eighty samples from 78 transplant patients had concomitant dd‐cfDNA, DSA and creatinine results. The median percentage of dd‐cfDNA in plasma samples with concomitant DSA negative results was significantly less than in DSA positive samples (0.37% vs. 3.15%, p = 0.002). There was no significant difference in the median percentage of dd‐cfDNA in plasma samples with concomitant samples with elevated creatinine levels (0.41% vs. 0.36%, p = 0.779). Thirty‐nine of these plasma samples had concomitant renal biopsy results. Thirty‐two biopsies were negative for rejection and seven were positive for rejection. A receiver operating characteristic curve analysis showed that dd‐cfDNA levels distinguished biopsy‐defined rejection from no rejection with an acceptable AUC of 0.737 (95% CI, 0.485–0.987). The %dd‐cfDNA threshold maximising overall correct classification was 0.7%. Using this threshold might have prevented 26 patients from undergoing renal biopsy unnecessarily, with two patients directed not to have a biopsy incorrectly (26 dd‐cfDNA values being true negatives and two false negatives; NPV: 93% (95% CI, 83%–100%)), which outperformed the NPV for DSA: 88% (95% CI, 77%–99%) and creatinine 85% (95% CI, 69%–100%). We showed that the optimal dd‐cfDNA threshold (0.7%) in this study was lower than the 1% threshold identified in non‐UK studies. AlloSeq cfDNA (CareDx) with the optimal threshold showed an acceptable level of discrimination of biopsy‐proven rejection and a potential to reduce the number of biopsies performed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Transplantation Laboratory, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK.
- Division of Endocrinology, Diabetes and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
- Diabetes, Endocrinology and Metabolism Centre, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Förderung
- National School of Healthcare Science Higher Specialist Scientist Training Programme
Zitieren
APA
Flynn, P. A., Rutter, M. K., & Burlinson, N. D. (2026). Donor‐Derived Cell‐Free DNA Levels Predict Renal Allograft Biopsy Findings in a UK Single‐Centre Study. Results of the KORAD Study. International Journal of Immunogenetics, 53(4), 332-343. https://doi.org/10.1111/iji.70055
Vancouver
Flynn PA, Rutter MK, Burlinson ND. Donor‐Derived Cell‐Free DNA Levels Predict Renal Allograft Biopsy Findings in a UK Single‐Centre Study. Results of the KORAD Study. International Journal of Immunogenetics. 2026;53(4):332-343. doi:10.1111/iji.70055
BibTeX
@article{Flynn2026,
author = {Flynn, Patrick A and Rutter, Martin K and Burlinson, Natalia Diaz},
title = {Donor‐Derived Cell‐Free DNA Levels Predict Renal Allograft Biopsy Findings in a UK Single‐Centre Study. Results of the KORAD Study},
journal = {International Journal of Immunogenetics},
year = {2026},
volume = {53},
number = {4},
pages = {332--343},
doi = {10.1111/iji.70055}
}
EUVIMED